P30

Announcing Cantaloupe LIVE, an Interactive Customer Event in Mexico City on 5 December!

Retrieved on: 
Thursday, November 16, 2023
Software, Supply Chain Management, Other Retail, IOT (Internet of Things), Payments, Consumer, Convenience Store, Technology, Food, Beverage, Retail, Other Consumer, Other Technology, P30, Cantaloupe, Inc., Smart lock, Cooler, Age verification system, RSVP, Temperature, Telemetry, Cantaloupe

Cantaloupe, Inc. (NASDAQ: CTLP), a digital payments and software services company that provides end-to-end technology solutions for self-service commerce, is showcasing its full suite of solutions for the Latin America market at Cantaloupe LIVE on 5 December 2023 in Mexico City.

Key Points: 
  • Cantaloupe, Inc. (NASDAQ: CTLP), a digital payments and software services company that provides end-to-end technology solutions for self-service commerce, is showcasing its full suite of solutions for the Latin America market at Cantaloupe LIVE on 5 December 2023 in Mexico City.
  • Retailers, convenience store operators, equipment manufacturers, entertainment and sports merchandisers, as well as micro market and vending operators, are all invited to attend!
  • The evening reception begins at 4:00 p.m. Those interested in attending should rsvp at https://go.cantaloupe.com/Cantaloupe-Live-Mexico-2023.html .
  • Guests will also experience the Cantaloupe Go line of solutions built specifically for Mexico and other Latin America markets.

Wistar Researchers Discover Possible New Treatment for Triple-Negative Breast Cancer

Retrieved on: 
Tuesday, September 19, 2023
TNBC, CRISPR, PBCC, Cell biology, University, Molecule, Nature Cancer, ACSS2, Culture, Genomics, DP2, HER2, Wistar, Breast, Infection, HIC, Cancer, Biomedical Research, Immunity, Jim Valvano, Research, Zhug, Bangladesh Technical Education Board, Ellen, National Cancer Institute, Triple-negative breast cancer, Patient, Metabolism, Wistar Institute, Immune system, University of Bologna, NCI, P30, NIH, Breast cancer, Vaccine

Schug’s paper — titled, “Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer” — demonstrates a double-acting mechanism for fighting a particularly aggressive, difficult-to-treat form of breast cancer.

Key Points: 
  • Schug’s paper — titled, “Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer” — demonstrates a double-acting mechanism for fighting a particularly aggressive, difficult-to-treat form of breast cancer.
  • Triple-negative breast cancer, or TNBC, affects 10-15% of patients with breast cancer in the US.
  • The absence of any of these receptors — receptors that, when present in other forms of breast cancer, can be effectively targeted during treatment — makes treating TNBC quite difficult, and patients with TNBC have limited treatment options.
  • TNBC’s notorious aggression makes the technical challenge of finding a reliably effective treatment target all the more serious: compared to other breast cancers, TNBC grows faster and resists treatment more stubbornly.

Wistar Researchers Discover Potential Target for Gastric Cancers Associated with Epstein-Barr Virus

Retrieved on: 
Tuesday, August 22, 2023
DNA, Cell biology, Methylation, MBio, Hereditary diffuse gastric cancer, Collaborative writing, Cone Health Women's Hospital, Culture, Wistar, Infection, Cancer, Biomedical Research, Epstein–Barr virus, Research, Gene expression, Cell, T32, National Institutes of Health, Bangladesh Technical Education Board, Harvard Medical School, Ellen, Cytosine, Coriell Institute for Medical Research, Genome, Epigenome, Wistar Institute, Tempera, Hospital, DNA methylation, Stomach, P30, NIH, Medical research, EBV, Vaccine, Pharmaceutical industry, Decitabine, Brigham

PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio .

Key Points: 
  • PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio .
  • In the paper, Wistar’s Tempera lab investigates the epigenetic characteristics of gastric cancer associated with the Epstein-Barr Virus: EBVaGC.
  • "Normally, a latent virus that reactivates and starts to kill cells is a bad thing.
  • Because lysis is lethal to cells, the epigenetic reactivation of lysis within gastric cancer associated with EBV offers a promising potential treatment for the specific subset of EBVaGC.

Wistar Researchers Discover Potential Target for Gastric Cancers Associated with Epstein-Barr Virus

Retrieved on: 
Tuesday, August 22, 2023
DNA, Cell biology, Methylation, MBio, Hereditary diffuse gastric cancer, Collaborative writing, Cone Health Women's Hospital, Culture, Wistar, Infection, Cancer, Biomedical Research, Epstein–Barr virus, Research, Gene expression, Cell, T32, National Institutes of Health, Bangladesh Technical Education Board, Harvard Medical School, Ellen, Cytosine, Coriell Institute for Medical Research, Genome, Epigenome, Wistar Institute, Tempera, Hospital, DNA methylation, Stomach, P30, NIH, Medical research, EBV, Vaccine, Pharmaceutical industry, Decitabine, Brigham

PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio .

Key Points: 
  • PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio .
  • In the paper, Wistar’s Tempera lab investigates the epigenetic characteristics of gastric cancer associated with the Epstein-Barr Virus: EBVaGC.
  • "Normally, a latent virus that reactivates and starts to kill cells is a bad thing.
  • Because lysis is lethal to cells, the epigenetic reactivation of lysis within gastric cancer associated with EBV offers a promising potential treatment for the specific subset of EBVaGC.

Potential New Targets Identified in Advanced Non-Alcoholic Fatty Liver Disease

Retrieved on: 
Thursday, January 5, 2023
Liver cancer, Fibrosis, Cancer, Icahn School of Medicine at Mount Sinai, Fatty liver disease, Cirrhosis, Mouse, Protein, Weizmann Institute of Science, Lung, Research, Scar, Type 2 diabetes, Institute of Liver and Biliary Sciences, NTRK3, NASH, University of California, Glass, Division, NAFLD, Non-alcoholic fatty liver disease, Liver failure, Disease, Hepatic stellate cell, Tissue, Yale School of Medicine, Liver disease, Patient, Mount Sinai, Science Translational Medicine, Heart, University, Hypertension, University of Edinburgh, Hepatitis, P30, Doctor of Philosophy, Sammi, Cell, Liver, Therapeutic discovery project, Medical imaging, Pharmaceutical industry, Dietary supplement, MD, Medicine

NEW YORK, Jan. 5, 2023 /PRNewswire-PRWeb/ -- Using the latest technologies—including both single-nuclear sequencing of mice and human liver tissue and advanced 3D glass imaging of mice to characterize key scar-producing liver cells—researchers have uncovered novel candidate drug targets for non-alcoholic fatty liver disease (NAFLD). The research was led by investigators at the Icahn School of Medicine at Mount Sinai.

Key Points: 
  • Using the latest technologies—including both single-nuclear sequencing of mice and human liver tissue and advanced 3D glass imaging of mice to characterize key scar-producing liver cells—researchers have uncovered novel candidate drug targets for non-alcoholic fatty liver disease (NAFLD).
  • Utilizing these innovative methods, the investigators discovered a network of cell-to-cell communication driving scarring as liver disease advances.
  • NEW YORK, Jan. 5, 2023 /PRNewswire-PRWeb/ -- Using the latest technologies—including both single-nuclear sequencing of mice and human liver tissue and advanced 3D glass imaging of mice to characterize key scar-producing liver cells—researchers have uncovered novel candidate drug targets for non-alcoholic fatty liver disease (NAFLD).
  • They identified a shared number of 68 pairs of potential drug targets across the two species.

Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments

Retrieved on: 
Monday, November 14, 2022
Research, Other Health, General Health, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Health Technology, Science, Biotechnology, Other Technology, Health, Other Science, U.S. News & World Report, Hospital, NCI, MD Anderson Cancer Center, Anderson, SEC filing, IACS, Drug development, Therapy, Patient, P30, Science, News, Precision medicine, Medicine, Cancer, Deep learning, Research, Security (finance), Physician, Risk, Annual report, Monroe Dunaway Anderson, Education, University, COVID-19, Drug discovery, Judgement, Therapeutic discovery project, Artificial intelligence, Global Monitoring Plan, National Cancer Institute, MD, Pharmaceutical industry

Exscientia plc (Nasdaq: EXAI) and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to align the patient-centric artificial intelligence (AI) capabilities of Exscientia with the drug discovery and development expertise of MD Anderson in order to advance novel small-molecule oncology therapies.

Key Points: 
  • Exscientia plc (Nasdaq: EXAI) and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to align the patient-centric artificial intelligence (AI) capabilities of Exscientia with the drug discovery and development expertise of MD Anderson in order to advance novel small-molecule oncology therapies.
  • Exscientia will collaborate with the team at IACS, a drug discovery engine focused on developing novel small-molecule therapeutics.
  • We are tremendously proud to work alongside MD Anderson to harness our AI-driven platform toward the discovery of next-generation cancer treatments.
  • Under the agreement terms, Exscientia and MD Anderson will jointly contribute to and support each program designated to move forward.

AB Capital Group Chooses Innovative SS&C Platform to Propel Business

Retrieved on: 
Monday, November 21, 2022
Cloud, P30, SS&C, SS, Senior, Architecture, Software, Wealth, Name, Capital Group Companies, Multimedia, SS&C Technologies, ABS Capital Partners, Risk, Aloha, Trust, ABOR, Bank, Management, Online shopping

WINDSOR, Conn., Nov. 21, 2022 /PRNewswire/ -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced AB Capital Group has chosen the new innovative platform SS&C Aloha to advance its investment operations, revamp core infrastructure and support its growth objectives.

Key Points: 
  • AB Capital Group manages P30 billion in equity, balanced and money market funds, and segregated investment and trust accounts.
  • "We aim to redefine and advance the wealth experience here in the Philippines with our new Private Wealth group," said Chrissi Morillo, Managing Director, AB Capital Private Wealth.
  • A boutique financial services provider, AB Capital Group focuses on wealth management, trust services, investment banking, and stock market investing.
  • The Group consists of: AB Capital Securities, Inc., one of the oldest and most trusted stock broking names in the industry; AB Capital Asset Management and Trust, with P30 billion in equity, balanced and money market funds under management; AB Capital Investment Banking, providing cutting-edge advice to corporations; and AB Capital Private Wealth, offering bespoke and expert solutions to the wealth journey of high-net-worth clients.

MD Anderson and ARTIDIS Announce Strategic Alliance to Advance Nanomechanical Technology Platform for Optimizing Cancer Treatment

Retrieved on: 
Monday, October 3, 2022
Cancer, Hospital, Achievement, National, NCI, Neoplasm, Technology, Immunotherapy, Anderson, Research, MD, Education, Monroe Dunaway Anderson, Lung cancer, Radiation therapy, U.S. News & World Report, Biopsy, MD Anderson Cancer Center, Cell, P30, Patient, National Cancer Institute, Diagnosis, University, AFM, GLOBE, News, Medical imaging, Pharmaceutical industry

MD Anderson clinicians will lead validation and proof-of-concept studies to evaluate the ARTIDIS technology as a tool for predicting response to treatment in multiple solid tumor indications.

Key Points: 
  • MD Anderson clinicians will lead validation and proof-of-concept studies to evaluate the ARTIDIS technology as a tool for predicting response to treatment in multiple solid tumor indications.
  • The strategic alliance with MD Anderson builds on a previous sponsored research agreement with James Welsh, M.D., professor of Radiation Oncology at MD Anderson, focusing on understanding immunotherapy resistance and response [1].
  • Additionally, ARTIDIS has shown that nanomechanical alteration in cancer tissue is a potentially suitable marker for cancer aggressiveness and indicator of treatment response.
  • MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

Children's Hospital Los Angeles Identifies Molecular Markers to Increase Precision in Treatment of Retinoblastoma

Retrieved on: 
Monday, September 26, 2022
Children, Biotechnology, Health, General Health, Pharmaceutical, Optical, Oncology, Medical Devices, Family, Hospitals, Consumer, Tao, National, USC Norris Comprehensive Cancer Center, Keck School of Medicine of USC, Children's Hospital Los Angeles, R35, Blog, P30, Patient, Physician, CHLA, Methylation, Nature Communications, Research, Mutation, Medicine, Death, Child, Pancreatic serous cystadenoma, Assistant, Cancer, No, Doctor of Philosophy, DNA, National Cancer Institute, YouTube, U.S. News & World Report, Hospital, Risk, MD, Neoplasm, News, USC, Instagram, Severe cognitive impairment, Humour, Children's Hospital, HIV disease progression rates, Rb, Twitter, Biomarker, LinkedIn, Gene, National Institutes of Health, Eye, Prognosis, Â, Fortis Healthcare, Diagnosis, Parent, Multimedia, Horizon Laser Vision Center Classic, Additional sex combs like 2, transcriptional regulator, Medical imaging, Pharmaceutical industry, Facebook, Retinoblastoma

View the full release here: https://www.businesswire.com/news/home/20220926005151/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220926005151/en/
    Jesse Berry, MD, surgeon, ocular oncologist and researcher at Children's Hospital Los Angeles (Photo: Business Wire)
    Because retinoblastoma occurs at the back of the eye, it is not readily observable.
  • Historically, the child would be presumed to have retinoblastoma, which is a genetic condition, and treated without a definitive diagnosis.
  • Founded in 1901, Childrens Hospital Los Angeles is the largest provider of care for children in Los Angeles County and is ranked the No.
  • The hospital also is home to the largest pediatric residency training program at a freestanding childrens hospital in the Western United States.

Virogin Biotech and MD Anderson Announce Strategic Collaboration to Accelerate Oncolytic Virus Research and Development for Treating Advanced Cancers

Retrieved on: 
Thursday, September 8, 2022
National, University, National Cancer Institute, Safety, Cancer, Tumor microenvironment, Research, Carcinoembryonic antigen, Therapy, CEA, News, U.S. News & World Report Best Hospitals Rankings, P30, MD Anderson Cancer Center, U.S. News & World Report, Monroe Dunaway Anderson, Dove Medical Press, Education, Hospital, GLOBE, Anderson, Oncolytic virus, Immunotherapy, Biomarker, NCI, Neoplasm, RNA transfection, Potyvirus, Trial of the century, Patient, Pharmaceutical industry, Vaccine

VANCOUVER, British Columbia & HOUSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Virogin Biotech, a clinical-stage biotech company, and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to accelerate the development of investigational treatments, including oncolytic viruses and immunotherapies, for patients with advanced cancers.

Key Points: 
  • VANCOUVER, British Columbia & HOUSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Virogin Biotech, a clinical-stage biotech company, and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to accelerate the development of investigational treatments, including oncolytic viruses and immunotherapies, for patients with advanced cancers.
  • The agreement brings together MD Anderson's clinical trials expertise and infrastructure with Virogin's innovative pipeline of investigational oncolytic viruses.
  • "We are pleased to collaborate with Virogin in this effort to accelerate the development of these novel cancer therapies."
  • MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).